Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-202 in Advanced Triple Negative Breast, Colorectal, and Urothelial Cancers
NCT07545122Phase 1Recruiting
- Sponsor
- Context Therapeutics
- Start
- Sep 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT-202 in triple-negative breast cancer (TNBC), colorectal cancer (CRC) and urothelial carcinoma (UC) (2 arms), sponsored by Context Therapeutics. Primary endpoints: Dose Limiting Toxicities at 28 days and Overall Response Rate at 24 months. Started Sep 2026; status: recruiting.
02
Drugs
CT-202
03
Conditions
triple-negative breast cancer (TNBC)colorectal cancer (CRC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07545122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545122.